Lukas Biomedical (ROCO:6814) ROCE % : -6.31% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Lukas Biomedical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lukas Biomedical's annualized ROCE % for the quarter that ended in Jun. 2023 was -6.31%.

Lukas Biomedical ROCE % Historical Data

The historical data trend for Lukas Biomedical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lukas Biomedical ROCE % Chart

Lukas Biomedical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

-2.97

-0.61

-1.17

-10.52

-11.41

Lukas Biomedical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial					-10.23	-10.76	-11.76	-9.95	-6.31

Lukas Biomedical ROCE % Calculation

Lukas Biomedical's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-46.999	/	( ( (531.241 - 130.538)	+	(479.666 - 56.445) )	/ 2 )
	=	-46.999	/	( (400.703	+	423.221)	/ 2 )
	=	-46.999	/	411.962
	=	-11.41 %

Lukas Biomedical's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-26.204	/	( ( (479.666 - 56.445)	+	(466.413 - 59.488) )	/ 2 )
	=	-26.204	/	( ( 423.221	+	406.925 )	/ 2 )
	=	-26.204	/	415.073
	=	-6.31 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Lukas Biomedical (ROCO:6814) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lukas Biomedical ROCE % Related Terms

Thank you for viewing the detailed overview of Lukas Biomedical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lukas Biomedical (ROCO:6814) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lukas Biomedical Inc (ROCO:6814) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xinyi Road, Da'an District, 3rd Floor, No. 2, Lane 265, Section 4, Taipei, TWN

Website

https://www.lukas-bio.com.tw

Lukas Biomedical Inc is engaged in the research and development of immunotherapy for cancer treatment technologies. It researches on the Memory T cell (LuLym-T) to improve the clinical outcome of cancer treatment.

Lukas Biomedical (ROCO:6814) Headlines

No Headlines